Leidos Holdings Q3 2026 earnings
Revenue growth decelerates to 4% as acquisition integration costs rise, but adjusted EPS jumps 19% and guidance is raised for the third consecutive quarter.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $4.63B | +4% | +1.5% | Ex. 99.1, Summary Operating Results |
| EPS (GAAP) | $3.28 | +16% | +17% | Ex. 99.1, Summary Operating Results |
| EPS (adjusted) | $3.62 | +19% | +11% | Ex. 99.1, Summary Operating Results |
| Net income | $413M | +12% | +16% | Ex. 99.1, Summary Operating Results |
| Adj. EBITDA | $644M | +5% | +2% | Ex. 99.1, Summary Operating Results |
| Adj. EBITDA margin | 13.9% | +1.1 pp | +0.1 pp | Ex. 99.1, Summary Operating Results |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Intelligence & Digital | $1.55B | +1.6% | 33.5% | Operating margin 11.1% |
| Health | $1.07B | -11.6% | 23.1% | Operating margin 22.5% |
| Homeland | $1.02B | +32.1% | 22.1% | Operating margin 7.9% |
| Defense | $992M | +3.4% | 21.4% | Operating margin 8.7% |
Margins and costs
- Gross margin N/A
- Operating expenses $3.82B (+5.5% YoY)
- One-offs in the quarter $12M in costs associated with recent strategic corporate transactions; $11M acquisition, integration and restructuring costs; $26M amortization of acquired intangibles; $5M asset impairment charges; $17M settlement loss on pension plan buy-out (YTD); $4M acquisition related financing costs (YTD)
- Effective tax rate 16.8% (prior-year 23.8%, year-to-date 18.9%)
- Non-GAAP bridge Adds back acquisition, integration and restructuring costs ($11M), amortization of acquired intangibles ($26M), asset impairment charges ($5M), settlement loss on pension plan buy-out ($17M), and acquisition related financing costs ($4M).
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Net bookings | $5.5B | $4.9B | $4.9B | +12% |
| Book-to-bill ratio | 1.2 | 1.1 | 1.1 | +9% |
| Backlog | $49.6B | $48.7B | $48.7B | +1.8% |
| Cash and cash equivalents | $630M | $748M | $748M | -16% |
| Debt | $6.0B | $6.0B | $6.0B | 0% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenues | $18.00 - $18.20B | $18.20 - $18.40B | -0.2 pp |
| Adjusted EBITDA Margin | Mid 13% | Mid 13% | 0 pp |
| Non-GAAP Diluted EPS | $12.50 - $12.70 | $12.20 - $12.50 | +0.3 pp |
| Cash Flows Provided by Operating Activities | Approximately $1.90B | Approximately $1.85B | +0.05 pp |
What drove it
- Revenue story Revenue grew 4% YoY, driven by defense tech, air traffic management, and intelligence mission support, partially offset by declines in managed health and federal civilian IT programs.
- EPS story Adjusted EPS rose 19% YoY, supported by improved program performance and disciplined cost management, while GAAP EPS benefited from a lower effective tax rate.
- One-off check $12M in costs associated with recent strategic corporate transactions (Q3 only).
The good
- Adjusted EPS up 19% YoY
- Adjusted EBITDA margin up 1.1 pp YoY
- Book-to-bill ratio of 1.2
- Backlog up 4% YoY
The bad
- Revenue growth decelerated to 4% YoY
- Health segment revenue down 11.6% YoY
- Non-GAAP Free Cash Flow down 30% YoY
The ugly
- none
Open questions
- How will the contribution of the Security Enterprise Solutions and Industrial Automation (SES) businesses to the joint venture impact future revenue and margin reporting?
- What specific factors caused the decline in managed health and federal civilian IT programs?
Full release
Leidos Holdings (LDOS) earnings release, November 3, 2026
Leidos Delivers Strong Third Quarter and Enhances Full-Year Guidance u
Revenues of $4.6 billion, up 4% year-over-year u
Net income of $413 million or $3.28 per diluted share u
Adjusted EBITDA (non-GAAP) of $644 million and Adjusted EBITDA margin (non-GAAP) of 13.9% u
Non-GAAP Diluted Earnings per Share of $3.62, up 19% year-over-year u
Cash Flows from Operations of $523 million; Non-GAAP Free Cash Flow of $476 million
RESTON, Va., November 3, 2026 – Leidos Holdings, Inc. (NYSE: LDOS) today reported financial results for the third quarter of fiscal year 2026, highlighted by robust revenue growth and free cash flow generation.
“Leidos delivered another quarter of strong financial performance, allowing us to enhance our 2026 guidance for the third consecutive quarter,” said Chief Executive Officer Tom Bell. “Our sustained momentum reflects the strength of our focused team, united behind our NorthStar 2030 strategy and committed to delivering on our customers’ most critical missions. Looking ahead, we’ll continue to execute our strategy with confidence, invest in differentiated capabilities, and deploy capital strategically to accelerate growth and create enduring value.”
SUMMARY OPERATING RESULTS
Revenues for the quarter were $4.63 billion, up 4% compared to the third quarter of 2025. Revenue grew year-over-year due to increased customer demand for defense tech products, air traffic management solutions, and intelligence mission support as well as the acquisition of ENTRUST Solutions, which offset declines in some managed health and federal civilian IT programs.
For the third quarter, net income was $413 million, or $3.28 per diluted share. Net income and diluted EPS were up 12% and 16%, respectively, year-over-year; net income margin was 8.9% compared to 8.3% in the third quarter of 2025. Net income and diluted EPS for the quarter reflect $12 million in costs associated with recent strategic corporate transactions. Adjusting for these and certain other items, non-GAAP net income increased 14% year-over-year, to $455 million for the third quarter, and non-GAAP diluted EPS increased 19% to $3.62. GAAP and non-GAAP earnings measures reflect a lower effective tax rate, primarily due to an increase in the federal research tax credit and a decrease in unrecognized tax benefits.
In addition, adjusted EBITDA was $644 million for the third quarter, up 5% year-over-year. Adjusted EBITDA margin of 13.9% increased from 13.8% in the third quarter of 2025. Profitability in the quarter was driven by improved program performance and disciplined cost management across the portfolio.
CASH FLOW SUMMARY
Net cash provided by operating activities for the quarter was $523 million for an operating cash flow conversion ratio of 128%. After adjusting for property, equipment, and software payments, quarterly free cash was $476 million for a free cash flow conversion ratio of 105%.
For the quarter, Leidos used $48 million in investing activities, including $47 million in property, equipment and software payments. Leidos used $549 million in financing activities, consisting primarily of $556 million returned to shareholders, including $504 million in share repurchases and $52 million as part of a regular quarterly cash dividend program. As of October 2, 2026, Leidos had $630 million in cash and cash equivalents and $6.0 billion of debt.
On October 30, 2026, the Leidos Board of Directors declared a cash dividend of $0.45 per share, which represents an increase of 4.7% over the prior quarter's dividend amount. The dividend will be payable on December 31, 2026, to stockholders of record at the close of business on December 15, 2026.
NEW BUSINESS AWARDS
Net bookings totaled $5.5 billion in the quarter, representing a book-to-bill ratio of 1.2. As a result, backlog at the end of the quarter was $49.6 billion, of which $11.1 billion was funded. Trailing-twelve-month book-to-bill of 1.1 resulted in year-over-year growth in total and funded backlog of 4% and 22%, respectively. Quarterly bookings included several key awards: u
U.S. Air Force Air Combat Command (ACC) Intelligence Directorate (A2) Intelligence, Surveillance, Reconnaissance (ISR).
Leidos secured a $717 million contract to continue providing critical threat mitigation and ISR operations support for the Air Force's ACC A2. Leidos is executing at 35 global locations, delivering embedded advanced data fusion across ACC headquarters, numbered Air Forces, and wings to ensure that the joint force maintains a decisive information advantage. u
Transportation Security Administration (TSA) Security Equipment Deployment Services (SEDS).
TSA awarded Leidos a $672 million contract to continue to deploy, relocate, and manage critical security screening equipment across all federalized U.S. airports and major domestic special events. This award builds upon more than a decade of Leidos supporting TSA infrastructure, leveraging their deep logistics and integration expertise to protect the nation's transportation systems and adapt swiftly to emerging security threats. u
Defense Health Agency (DHA) Military Health System (MHS) GENESIS Bridge.
Leidos secured a 12-month, $318 million sole-source bridge contract to sustain and enhance MHS GENESIS, including system maintenance, cybersecurity, performance monitoring, technology updates, and end-user support. The award ensures continuity of critical operations while reinforcing Leidos' expertise in modernizing complex federal health systems and delivering technology that supports healthcare for service members and their families. u
U.S. Army Defensive Cyber Solutions Branch (DCSB) Defensive Cyber Operations (DCO) 2.0.... (truncated)latform. The platform utilizes autonomous AI agents that dramatically compresses threat response windows and eliminates analyst alert fatigue to ensure a hardened, reliable global network capable of defending against growing and evolving threats. u
Space Development Agency (SDA) Accelerated Missile Defense Tranche 3 (AMDT3).
Leidos secured a $272 million award from Sierra Space to provide infrared sensing payloads, onboard signal-processing capabilities, and mission support for the AMDT3 Tracking Layer. The payloads will fly on 18 missile-tracking satellites, which are designed to detect hypersonic and other advanced threats from Low Earth Orbit. This award expands Leidos' position in space sensing and onboard digital processing, and builds on its execution record on Tranches 0, 1, and 2. u
United Kingdom (UK) National Air Traffic Services (NATS) Flight Data Processing (FDP) Evolution.
Leidos received a $170 million contract to upgrade the core flight data processing software under the UK NATS FDP Evolutions program, replacing legacy systems with a modern architecture that automatically delivers real-time flight data to air traffic controllers. This award strengthens Leidos' global position in next-generation air traffic management and reinforces its pedigree for upcoming modernization projects. u
U.S. Cyber Command (CYBERCOM) Cyberspace Operations Support Services (COSS).
Leidos secured a five-year, $160 million contract to support USCYBERCOM's J3, Cyber National Mission Force, and Joint Task Force Area with planning, training, strategy, doctrine development, and campaign assessment. This award marks Leidos' first cyber operations award with USCYBERCOM and establishes a prime foothold with a strategically important customer in a high-growth national security mission area. u
U.S. Navy Nuclear-Armed Sea-Launched Cruise Missile (SLCM-N).
The Navy awarded Leidos a $155 million contract to continue to advance flight systems integration and flight vehicle subsystem development for a sea-based theater nuclear deterrent. u
Customer & Border Patrol (CBP) and Immigration & Customs Enforcement (ICE) Shared Electronic Health Record (EHR) Platform and Support Services.
Leidos secured a five-year, $129 million single-award blanket purchase agreement (BPA) to implement and sustain a modern EHR system for U.S. CBP and ICE. Under the initial call order, Leidos will deploy an integrated EHR system for ICE, consolidating core healthcare capabilities, enabling secure information exchange, and improving continuity of care. Building on the company's MHS GENESIS success, the award establishes and foundation for expansion across Department of Homeland Security (DHS) components. u
U.S. Army Long-Range Persistent Surveillance—Mobile (ALPS-M) and U.S. Marine Corps Multi-Role Air Defense Radar (MRADR).
The Army awarded Leidos a $95 million contract to deliver 10 prototypes of its current ALPS capability, which is being deployed globally through the U.S. Air Force's Air Base Air Defense System - Missile Defense (ABADS-MD) program. Separately, Leidos secured a $41 million contract to build 14 additional MRADR systems for the Marine Corps. Together, these awards demonstrate sustained customer demand for Leidos' family of persistent surveillance sensing technologies. u
AGM-190A Small Cruise Missile (SCM) Program.
T he U.S. Special Operations Command awarded Leidos a $27 million contract for the Low-Rate Initial Production (LRIP) of the AGM-190A Havoc Spear SCM. Under this award, Leidos will deliver an initial quantity of 45 All Up Rounds for operational fielding in Air Force Special Operations Command (AFSOC). Havoc Spear has the potential to be broadly deployed across special operations and conventional military platforms for low-cost precision strike mass capability in contested environments.
FORWARD GUIDANCE
On October 5, 2026, Leidos closed the Contribution and Equity Purchase Agreement with Altaris, contributing the Security Enterprise Solutions and Industrial Automation (SES) businesses to a newly formed joint venture. After adjusting for the Joint Venture and incorporating its year-to-date performance and current outlook, Leidos is adjusting its fiscal year 2026 guidance as follows:
For information regarding adjusted EBITDA margin and non-GAAP diluted EPS, see the related explanations and reconciliations to GAAP measures included elsewhere in this release.
Leidos does not provide a reconciliation of forward-looking adjusted EBITDA margins or non-GAAP diluted EPS to net income margin or diluted EPS due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income margin or diluted EPS may vary significantly based on actual events, Leidos is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected net income margin and diluted EPS being materially less than what may be implied by projected adjusted EBITDA margins and non-GAAP diluted EPS.
CONFERENCE CALL INFORMATION
Leidos management will discuss operations and financial results in an earnings conference call beginning at 8 A.M. eastern time on November 3, 2026. A live audio broadcast of the conference call along with a supplemental presentation will be available to the public through links on the Leidos Investor Relations website ( http://ir.leidos.com).
An archived version of the webcast will be available on the Leidos Investor Relations website until November 3, 2027.
ABOUT LEIDOS... (truncated)d annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.leidos.com.
Financial statements
Income Statement
Three Months Ended — SUMMARY OPERATING RESULTS (in millions, except margin and per share data)
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | |
|---|---|---|
| Revenues | 4,630 | 4,469 |
| Net income | 413 | 369 |
| Net income margin | 8.9% | 8.3% |
| Diluted earnings per share (EPS) | 3.28 | 2.82 |
| Non-GAAP Measures*: | ||
| Adjusted EBITDA | 644 | 616 |
| Adjusted EBITDA margin | 13.9% | 13.8% |
| Non-GAAP diluted EPS | 3.62 | 3.05 |
| * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. | * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. | * Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the information provided in accordance with GAAP. Management believes that these non-GAAP measures provide another representation of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. See Non-GAAP Financial Measures at the end of this press release for more information and a reconciliation of our selected reported results to these non-GAAP measures. |
Income Statement
| FY26 Guidance – Current | FY26 Guidance – Prior | |
|---|---|---|
| Revenues (B) | $18.00 - $18.20 | $18.20 - $18.40 |
| Adjusted EBITDA Margin | Mid 13% | Mid 13% |
| Non-GAAP Diluted EPS | $12.50 - $12.70 | $12.20 - $12.50 |
| Cash Flows Provided by Operating Activities (B) | Approximately $1.90 | Approximately $1.85 |
Income Statement
Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data)
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | Nine Months Ended – October 2, 2026 | Nine Months Ended – October 3, 2025 | |
|---|---|---|---|---|
| Revenues | 4,630 | 4,469 | 13,588 | 12,967 |
| Cost of revenues | 3,810 | 3,648 | 11,190 | 10,607 |
| Selling, general and administrative expenses | 262 | 290 | 768 | 737 |
| Acquisition, integration and restructuring costs | 12 | 4 | 74 | 10 |
| Equity earnings of non-consolidated subsidiaries | -7 | -8 | -19 | -23 |
| Operating income | 553 | 535 | 1,575 | 1,636 |
| Non-operating expense: | ||||
| Interest expense, net | -67 | -51 | -191 | -155 |
| Other expense, net | -4 | -22 | -1 | |
| Income before income taxes | 482 | 484 | 1,362 | 1,480 |
| Income tax expense | -69 | -115 | -258 | -353 |
| Net income | 413 | 369 | 1,104 | 1,127 |
| Less: net income attributable to non-controlling interest | 3 | 2 | 12 | 6 |
| Net income attributable to Leidos common stockholders | 410 | 367 | 1,092 | 1,121 |
| Earnings per share: | ||||
| Basic | 3.31 | 2.87 | 8.74 | 8.69 |
| Diluted | 3.28 | 2.82 | 8.67 | 8.62 |
| Weighted average number of common shares outstanding: | ||||
| Basic | 124 | 128 | 125 | 129 |
| Diluted | 125 | 130 | 126 | 130 |
| Cash dividends declared per share | 0.43 | 0.4 | 1.29 | 1.2 |
Income Statement
Three Months Ended — UNAUDITED SEGMENT OPERATING RESULTS (in millions)
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | Nine Months Ended – October 2, 2026 | Nine Months Ended – October 3, 2025 | |
|---|---|---|---|---|
| Intelligence & Digital | 1,546 | 1,525 | 4,558 | 4,341 |
| Health | 1,068 | 1,210 | 3,342 | 3,573 |
| Homeland | 1,024 | 775 | 2,858 | 2,316 |
| Defense | 992 | 959 | 2,830 | 2,737 |
| Total | 4,630 | 4,469 | 13,588 | 12,967 |
| Operating income (loss): | ||||
| Intelligence & Digital | 171 | 141 | 459 | 408 |
| Health | 240 | 324 | 778 | 915 |
| Homeland | 81 | 50 | 206 | 175 |
| Defense | 86 | 79 | 232 | 231 |
| Corporate | -25 | -59 | -100 | -93 |
| Total | 553 | 535 | 1,575 | 1,636 |
| Operating income margin: | ||||
| Intelligence & Digital | 11.1 | 9.2 | 10.1 | 9.4 |
| Health | 22.5 | 26.8 | 23.3 | 25.6 |
| Homeland | 7.9 | 6.5 | 7.2 | 7.6 |
| Defense | 8.7 | 8.2 | 8.2 | 8.4 |
| Total | 11.9 | 12 | 11.6 | 12.6 |
Income Statement
Three Months Ended October 2, 2026
| Three Months Ended October 2, 2026 – As reported | Three Months Ended October 2, 2026 – Acquisition, integration and restructuring costs | Three Months Ended October 2, 2026 – Amortization of acquired intangibles | Asset impairment charges | Non-GAAP results | |
|---|---|---|---|---|---|
| Operating income | 553 | 12 | 35 | 7 | 607 |
| Non-operating expense, net | -71 | -71 | |||
| Income before income taxes | 482 | 12 | 35 | 7 | 536 |
| Income tax expense(1) | -69 | -1 | -9 | -2 | -81 |
| Net income | 413 | 11 | 26 | 5 | 455 |
| Less: net income attributable to non-controlling interest | 3 | 3 | |||
| Net income attributable to Leidos common stockholders | 410 | 11 | 26 | 5 | 452 |
| Diluted EPS attributable to Leidos common stockholders(2) | 3.28 | 0.09 | 0.21 | 0.04 | 3.62 |
| Diluted shares | 125 | 125 | 125 | 125 | 125 |
Income Statement
Three Months Ended October 3, 2025
| Three Months Ended October 3, 2025 – As reported | Three Months Ended October 3, 2025 – Acquisition, integration and restructuring costs | Three Months Ended October 3, 2025 – Amortization of acquired intangibles | Three Months Ended October 3, 2025 – Asset impairment charges | Three Months Ended October 3, 2025 – Non-GAAP results | |
|---|---|---|---|---|---|
| Operating income | 535 | 4 | 33 | 3 | 575 |
| Non-operating expense, net | -51 | -51 | |||
| Income before income taxes | 484 | 4 | 33 | 3 | 524 |
| Income tax expense(1) | -115 | -1 | -8 | -1 | -125 |
| Net income | 369 | 3 | 25 | 2 | 399 |
| Less: net income attributable to non-controlling interest | 2 | 2 | |||
| Net income attributable to Leidos common stockholders | 367 | 3 | 25 | 2 | 397 |
| Diluted EPS attributable to Leidos common stockholders(2) | 2.82 | 0.02 | 0.19 | 0.02 | 3.05 |
| Diluted shares | 130 | 130 | 130 | 130 | 130 |
Income Statement
Three Months Ended October 3, 2025
| Three Months Ended October 3, 2025 – As reported | Three Months Ended October 3, 2025 – Acquisition, integration and restructuring costs | Three Months Ended October 3, 2025 – Amortization of acquired intangibles | Three Months Ended October 3, 2025 – Asset impairment charges | Three Months Ended October 3, 2025 – Non-GAAP results | |
|---|---|---|---|---|---|
| Net income | 369 | 3 | 25 | 2 | 399 |
| Income tax expense(1) | 115 | 1 | 8 | 1 | 125 |
| Income before income taxes | 484 | 4 | 33 | 3 | 524 |
| Depreciation expense | 40 | 40 | |||
| Amortization of intangibles | 34 | -33 | 1 | ||
| Interest expense, net | 51 | 51 | |||
| Adjusted EBITDA | 609 | 4 | 3 | 616 | |
| Adjusted EBITDA margin | 13.6 | 13.8 |
Income Statement
Nine Months Ended October 2, 2026
| Nine Months Ended October 2, 2026 – As reported | Nine Months Ended October 2, 2026 – Acquisition, integration and restructuring costs(1) | Nine Months Ended October 2, 2026 – Amortization of acquired intangibles | Nine Months Ended October 2, 2026 – Asset impairment charges | Nine Months Ended October 2, 2026 – Settlement loss on pension plan buy-out | Nine Months Ended October 2, 2026 – Acquisition related financing costs | Nine Months Ended October 2, 2026 – Non-GAAP results | |
|---|---|---|---|---|---|---|---|
| Operating income | 1,575 | 76 | 105 | 8 | 1,764 | ||
| Non-operating expense, net | -213 | 23 | 5 | -185 | |||
| Income before income taxes | 1,362 | 76 | 105 | 8 | 23 | 5 | 1,579 |
| Income tax expense(2) | -258 | -10 | -26 | -2 | -6 | -1 | -303 |
| Net income | 1,104 | 66 | 79 | 6 | 17 | 4 | 1,276 |
| Less: net income attributable to non-controlling interest | 12 | 12 | |||||
| Net income attributable to Leidos common stockholders | 1,092 | 66 | 79 | 6 | 17 | 4 | 1,264 |
| Diluted EPS attributable to Leidos common stockholders(3) | 8.67 | 0.52 | 0.63 | 0.05 | 0.13 | 0.03 | 10.03 |
| Diluted shares | 126 | 126 | 126 | 126 | 126 | 126 | 126 |
Income Statement
Nine Months Ended October 2, 2026
| Nine Months Ended October 2, 2026 – As reported | Nine Months Ended October 2, 2026 – Acquisition, integration and restructuring costs(1) | Nine Months Ended October 2, 2026 – Amortization of acquired intangibles | Nine Months Ended October 2, 2026 – Asset impairment charges | Nine Months Ended October 2, 2026 – Settlement loss on pension plan buy-out | Nine Months Ended October 2, 2026 – Acquisition related financing costs | Nine Months Ended October 2, 2026 – Non-GAAP results | Nine Months Ended October 2, 2026 – Non-GAAP results | |
|---|---|---|---|---|---|---|---|---|
| Net income | 1,104 | 66 | 79 | 6 | 17 | 4 | 1,276 | |
| Income tax expense(2) | 258 | 10 | 26 | 2 | 6 | 1 | 303 | |
| Income before income taxes | 1,362 | 76 | 105 | 8 | 23 | 5 | 1,579 | |
| Depreciation expense | 124 | 124 | ||||||
| Amortization of intangibles | 105 | -105 | ||||||
| Interest expense, net | 191 | -5 | 186 | |||||
| Adjusted EBITDA | 1,782 | 76 | 8 | 23 | 1,889 | |||
| Adjusted EBITDA margin | 13.1 | 13.9 | % |
Income Statement
Nine Months Ended October 3, 2025
| Nine Months Ended October 3, 2025 – As reported | Nine Months Ended October 3, 2025 – Acquisition, integration and restructuring costs(1) | Nine Months Ended October 3, 2025 – Amortization of acquired intangibles | Nine Months Ended October 3, 2025 – Asset impairment charges | Nine Months Ended October 3, 2025 – Non-GAAP results | |
|---|---|---|---|---|---|
| Operating income | 1,636 | 11 | 95 | 3 | 1,745 |
| Non-operating expense, net | -156 | -156 | |||
| Income before income taxes | 1,480 | 11 | 95 | 3 | 1,589 |
| Income tax expense(2) | -353 | -2 | -24 | -1 | -380 |
| Net income | 1,127 | 9 | 71 | 2 | 1,209 |
| Less: net income attributable to non-controlling interest | 6 | 6 | |||
| Net income attributable to Leidos common stockholders | 1,121 | 9 | 71 | 2 | 1,203 |
| Diluted EPS attributable to Leidos common stockholders(3) | 8.62 | 0.07 | 0.55 | 0.02 | 9.25 |
| Diluted shares | 130 | 130 | 130 | 130 | 130 |
Income Statement
Nine Months Ended October 3, 2025
| Nine Months Ended October 3, 2025 – As reported | Nine Months Ended October 3, 2025 – Acquisition, integration and restructuring costs(1) | Nine Months Ended October 3, 2025 – Amortization of acquired intangibles | Nine Months Ended October 3, 2025 – Asset impairment charges | Nine Months Ended October 3, 2025 – Non-GAAP results | |
|---|---|---|---|---|---|
| Net income | 1,127 | 9 | 71 | 2 | 1,209 |
| Income tax expense(2) | 353 | 2 | 24 | 1 | 380 |
Balance Sheet
October 2, 2026 — UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share and per share data)
| October 2, 2026 | January 2, 2026 | |
|---|---|---|
| Cash and cash equivalents | 630 | 1,108 |
| Receivables, net | 2,944 | 2,708 |
| Inventory, net | 90 | 342 |
| Other current assets | 512 | 656 |
| Assets held for sale | 904 | |
| Total current assets | 5,080 | 4,814 |
| Property, plant and equipment, net | 913 | 961 |
| Intangible assets, net | 879 | 458 |
| Goodwill | 7,725 | 6,342 |
| Operating lease right-of-use assets, net | 475 | 526 |
| Other long-term assets | 394 | 392 |
| Total assets | 15,466 | 13,493 |
| Liabilities: | ||
| Accounts payable and accrued liabilities | 2,175 | 1,988 |
| Accrued payroll and employee benefits | 813 | 819 |
| Current portion of long-term debt | 18 | 20 |
| Liabilities held for sale | 171 | |
| Total current liabilities | 3,177 | 2,827 |
| Long-term debt, net of current portion | 6,009 | 4,628 |
| Operating lease liabilities | 537 | 587 |
| Other long-term liabilities | 518 | 489 |
| Total liabilities | 10,241 | 8,531 |
| Stockholders’ equity: | ||
| Additional paid-in capital | 319 | |
| Retained earnings | 5,197 | 4,647 |
| Accumulated other comprehensive loss | -25 | -50 |
| Total Leidos stockholders’ equity | 5,172 | 4,916 |
| Non-controlling interest | 53 | 46 |
| Total stockholders' equity | 5,225 | 4,962 |
| Total liabilities and stockholders' equity | 15,466 | 13,493 |
Cash Flow
Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | Nine Months Ended – October 2, 2026 | Nine Months Ended – October 3, 2025 | |
|---|---|---|---|---|
| Net income | 413 | 369 | 1,104 | 1,127 |
| Adjustments to reconcile net income to net cash provided by operations: | ||||
| Depreciation and amortization | 76 | 74 | 229 | 215 |
| Stock-based compensation | 28 | 26 | 79 | 72 |
| Deferred income taxes | 15 | 88 | 13 | 288 |
| Net loss on pension plan settlement | 20 | |||
| Other | 13 | 7 | 27 | 7 |
| Change in assets and liabilities, net of effects of acquisitions and dispositions: | ||||
| Receivables | 35 | -61 | -158 | -297 |
| Other current assets and other long-term assets | 20 | 60 | 58 | 26 |
| Accounts payable and accrued liabilities and other long-term liabilities | -79 | 152 | 18 | -108 |
| Accrued payroll and employee benefits | -46 | -17 | -12 | -10 |
| Income taxes receivable/payable | 48 | 13 | 239 | -65 |
| Net cash provided by operating activities | 523 | 711 | 1,617 | 1,255 |
| Cash flows from investing activities: | ||||
| Acquisition of a business, net of cash acquired | -7 | -2,338 | -292 | |
| Payments for property, equipment and software | -47 | -31 | -110 | -82 |
| Divestiture of a business | 4 | |||
| Net proceeds from sale of assets | 4 | |||
| Other | -1 | 2 | -5 | 2 |
| Net cash used in investing activities | -48 | -36 | -2,445 | -372 |
| Cash flows from financing activities: | ||||
| Proceeds from debt issuance | 1,397 | 997 | ||
| Repayments of borrowings | -5 | -455 | -15 | -1,014 |
| Payments for debt issuance costs | -15 | -7 | ||
| Dividend payments | -52 | -51 | -162 | -156 |
| Repurchases of stock and other | -504 | -102 | -819 | -639 |
| Proceeds from issuances of stock | 14 | 16 | 47 | 47 |
| Net capital distributions to non-controlling interests | -2 | -2 | -5 | -9 |
| Other | -1 | -7 | -7 | |
| Net cash (used in) provided by financing activities | -549 | -595 | 421 | -788 |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | -3 | 11 | ||
Cash Flow
Three Months Ended — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [CONTINUED] (in millions)
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | Nine Months Ended – October 2, 2026 | Nine Months Ended – October 3, 2025 | |
|---|---|---|---|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash, including cash classified in current assets held for sale | -74 | 77 | -407 | 106 |
| Less: change in cash balances classified as assets held for sale | -18 | 23 | ||
| Net (decrease) increase in cash, cash equivalents and restricted cash | -56 | 77 | -430 | 106 |
| Cash, cash equivalents and restricted cash at beginning of period | 830 | 1,020 | 1,204 | 991 |
| Cash, cash equivalents and restricted cash at end of period | 774 | 1,097 | 774 | 1,097 |
Cash Flow
Three Months Ended
| Three Months Ended – October 2, 2026 | Three Months Ended – October 3, 2025 | |
|---|---|---|
| Net cash provided by operating activities | 523 | 711 |
| Payments for property, equipment and software | -47 | -31 |
| Non-GAAP free cash flow | 476 | 680 |
| Net income attributable to Leidos common stockholders | 410 | 367 |
| Acquisition, integration and restructuring costs(1) | 11 | 3 |
| Amortization of acquired intangibles(1) | 26 | 25 |
| Asset impairment charges(1) | 5 | 2 |
| Non-GAAP net income attributable to Leidos common stockholders | 452 | 397 |
| Operating cash flow conversion ratio | 128 | 194 |
| Non-GAAP free cash flow conversion ratio | 105 | 171 |
FORWARD-LOOKING STATEMENTS
Certain statements in this release contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements in this release include, among others, estimates of our future growth, strategy and financial and operating performance, including future revenues, adjusted EBITDA margins, diluted EPS (including on a non-GAAP basis) and cash flows provided by operating activities, as well as statements about our business contingency plans, government budgets and spending, uncertainties in tax due to new tax legislation or other regulatory developments, strategy, planned investments including the pending joint venture, sustainability goals and our future dividends, share repurchases, capital expenditures, debt repayments, acquisitions, dispositions and cash flow conversion. These statements reflect our belief and assumptions as to future events that may not prove to be accurate.
Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this release depending on a variety of factors, including, but not limited to: developments in the U.S. government defense and non-defense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, potential future U.S. government shutdown and other or future delays in the U.S. government budget process, or the U.S. government’s failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; deterioration of economic conditions or weakening in credit or capital markets; uncertainty in the consequences of current and future geopolitical events; inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company; our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to respond rapidly to emerging technology trends, including the use of artificial intelligence; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of an epidemic, pandemic or similar outbreak may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer, disposal and other processing, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts; the failure of our inspection or detection systems to detect threats; the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our... (truncated)vercome these and other known and unknown risks that we face.
These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission (SEC), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, all of which may be viewed or obtained through the Investor Relations section of our website at www.leidos.com.
All information in this release is as of
November 3, 2026. Leidos expressly disclaims any duty to update the guidance or any other forward-looking statement provided in this release to reflect subsequent events, actual results or changes in Leidos' expectations. Leidos also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.